Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost

Japanese Journal of Ophthalmology

Volumn 54, Issue 1, 2010, Pages 7-14

  Yamazaki, Sei ^a   Nanno, Mami ^b   Kimura, Tairo ^c   Suzumura, Hirotaka ^d   Yoshikawa, Keiji ^e  

^a Yamazaki Eye Clinic   (Japan)

^b Nihonmatsu Eye Hospital   (Japan)

^c Ueno Eye Clinic   (Japan)

^d Nakano General Hospital   (Japan)

^e Yoshikawa Eye Clinic   (Japan)

Author keywords

Benzalkonium chloride; Latanoprost; SofZia; Superficial punctate keratopathy; Travoprost

Indexed keywords

AGENTS ACTING ON THE EYE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARTIFICIAL TEAR; BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; EYE DROPS; HYALURONIC ACID; LATANOPROST; OLOPATADINE; PIRENOXINE; PRESERVATIVE; SOFZIA; TRAVATAN Z; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DISEASE SEVERITY; DRUG SUBSTITUTION; EYE IRRITATION; FEMALE; FOREIGN BODY SENSATION; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATOPATHY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SENSORY DYSFUNCTION; STATISTICAL MODEL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CLOPROSTENOL; CORNEAL DISEASES; FEMALE; FLUOROPHOTOMETRY; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR;

EID: 77249134758     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-009-0754-8     Document Type: Article

References (25)

1. C. Baudouin 2008 Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma Acta Ophthalmol 86 716 726 18537937
2. R. Noecker 2001 Effects of common ophthalmic preservatives on ocular health Adv Ther 18 205 215 10.1007/BF02853166 1:CAS:528:DC%2BD38Xjsl2qsw%3D%3D 11783457
3. Y. Kitazawa Latanoprost Study Group 2006 An open-label multicenter study on the efficacy and safety of topical use of latanoprost for 156 weeks Rinsho Ganka (Jpn J Clin Ophthalmol) 60 2047 2054
4. B. McCarey H. Edelhauser 2007 In vivo corneal epithelial permeability following treatment with prostaglandin analogs J Ocul Pharmacol Ther 23 445 451 10.1089/jop.2007.0024 1:CAS:528:DC%2BD2sXht1SmtbzK 17941807 (Pubitemid 350202478)
5. R.L. Gross J.H. Peace S.E. Smith, et al. 2008 Duration of IOP reduction with travoprost BAK-free solution J Glaucoma 17 217 222 10.1097/IJG. 0b013e31815a3472 18414108 (Pubitemid 351543547)
6. C. Baudouin L. Riancho J.M. Warnet F. Brignole 2007 In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost Invest Ophthalmol Vis Sci 48 4123 4128 10.1167/iovs.07-0266 17724196 (Pubitemid 351261038)
7. M.Y. Kahook R.J. Noecker 2008 Comparison of corneal and conjunctival changes after dosing of travoprost preserved with SofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears Cornea 27 339 343 10.1097/ICO.0b013e31815cf651 18362664
8. M.A. Lemp 1995 Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes CLAO J 21 221 232 1:STN:280:DyaK287itVOmtw%3D%3D 8565190
9. A.M. Bawazeer W.G. Hodge 2003 One-minute Schirmer test with anesthesia Cornea 22 285 287 10.1097/00003226-200305000-00001 12792467 (Pubitemid 36578522)
10. Standard least squares: random effects. In: JMP statistics and graphics guide, release 7. Cary, North Carolina: SAS Institute; 2007. p. 341-357.
11. A. Yafune T. Funatogawa M. Ishiguro 2005 Extended information criterion (EIC) approach for linear mixed effects models under restricted maximum likelihood (REML) estimation Stat Med 24 3417 3429 10.1002/sim.2191 16237658 (Pubitemid 41645383)
12. J.R. Phillips 2005 Monovision slows juvenile myopia progression unilaterally Br J Ophthalmol 89 1196 1200 10.1136/bjo.2004.064212 1:STN:280:DC%2BD2MvksFWltg%3D%3D 16113381 (Pubitemid 41224474)
13. C. Hanna J.E. O'Brien 1960 Cell production and migration in the epithelial layer of the cornea Arch Ophthalmol 64 536 539 1:STN:280: DyaF3c%2FjtVyjsw%3D%3D 13711262
14. J.C. Henry J.H. Peace J.A. Stewart W.C. Stewart 2008 Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy Clin Ophthalmol 2 613 621 1:CAS:528: DC%2BD1cXhtlaksLvJ 19668762
15. Kanski JJ. Disorders of the cornea and sclera. In: Clinical ophthalmology. London: Butterworths; 1984. p. 5.2-5.31.
16. E.W. Leung F.A. Medeiros R.N. Weinreb 2008 Prevalence of ocular surface disease in glaucoma patients J Glaucoma 17 350 355 10.1097/IJG.0b013e31815c5f4f 18703943
17. N.N. Daoud N.A. Dickinson P. Gilbert 1983 Antimicrobial activity and physico-chemical properties of some alkyldimethylbenzylammonium chlorides Microbios 37 73 85 1:CAS:528:DyaL3sXltlKkt7c%3D 6413825
18. K. Inoue K. Okugawa S. Kato, et al. 2003 Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy J Glaucoma 12 480 485 10.1097/00061198-200312000-00007 14646683 (Pubitemid 37494176)
19. J.M. Guenoun C. Baudouin P. Rat A. Pauly J.M. Warnet F. Brignole-Baudouin 2005 In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva derived epithelial cells Invest Ophthalmol Vis Sci 46 2444 2450 10.1167/iovs.04-1331 15980234 (Pubitemid 43119492)
20. J.M. Guenoun C. Baudouin P. Rat A. Pauly J.M. Warnet F. Brignole-Baudouin 2005 In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells Invest Ophthalmol Vis Sci 46 4594 4599 10.1167/iovs.05-0776 16303954 (Pubitemid 44264559)
21. N. Li X.M. Chen Y. Zhou M.L. Wei X. Yao 2006 Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials Clin Exp Ophthalmol 34 755 764 10.1111/j.1442-9071.2006.01237.x (Pubitemid 44650150)
22. P. Denis A. Lafuma B. Khoshnood V. Mimaud G. Berdeaux 2007 A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy Curr Med Res Opin 23 601 608 10.1185/030079907X178720 1:CAS:528:DC%2BD2sXkt1Wrsr4%3D 17355741 (Pubitemid 46456908)
23. R.A. Lewis G.J. Katz M.J. Weiss, et al. 2007 Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy J Glaucoma 16 98 103 10.1097/01.ijg.0000212274.50229.c6 17224758 (Pubitemid 46114782)
24. R.S. Kumar V.W. Istiantoro S.T. Hoh C.L. Ho F.T. Oen T. Aung 2007 Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma J Glaucoma 16 606 609 10.1097/IJG.0b013e318050ab7a 18091178 (Pubitemid 350307612)
25. K. Miyata S. Amano M. Sawa T. Nishida 2003 A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability Arch Ophthalmol 121 1537 1539 10.1001/archopht.121.11. 1537 14609908 (Pubitemid 37392355)